Pharmaceutical Preparations · DE · CIK 2035832
Aktis Oncology develops targeted alpha radiopharmaceuticals for solid tumors, aiming for broad patient access
Comparable business profile · signals at a glance
In the 90 days to Jan 12, 2026: 6 insiders bought $114.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 12, 2026 | Nodelman OlegDirector | Buy | 2,077,779 | $18.00 | $37.4M |
| Jan 12, 2026 | Mpm Oncology Innovations Fund LpTenPercentOwner | Buy | 1,112,777 | $18.00 | $20.0M |
| Jan 12, 2026 | Gadicke AnsbertTenPercentOwner | Buy | 1,112,777 | $18.00 | $20.0M |
| Jan 12, 2026 | Vida Ventures Ii-A, LlcTenPercentOwner | Buy | 812,455 | $18.00 | $14.6M |
| Jan 12, 2026 | Kim Helen SusanDirector,TenPercentOwner | Buy | 812,455 | $18.00 | $14.6M |
| Jan 12, 2026 | Foley ToddDirector,TenPercentOwner | Buy | 232,870 | $18.00 | $4.2M |
| Jan 12, 2026 | Nodelman OlegDirector | Buy | 144,443 | $18.00 | $2.6M |
| Jan 12, 2026 | Vida Ventures Ii-A, LlcTenPercentOwner | Buy | 22,545 | $18.00 | $406K |
| Jan 12, 2026 | Kim Helen SusanDirector,TenPercentOwner | Buy | 22,545 | $18.00 | $406K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.